Porcine rotavirus type A VP8 protein: an antigen with dual functions as a subunit vaccine and serological diagnostic agent, from receptor binding to mucosal and systemic immunity

Authors:

Abstract
Porcine group A rotavirus (PoRVA) continues to be a significant cause of neonatal diarrhea in pigs, affecting swine production globally. VP8*, the glycan-binding domain of VP4, is crucial for viral attachment and immune activation. The dual role of VP8* makes it a promising candidate for vaccines and serological monitoring. However, research faces limitations due to genotype-specific receptor variations, inadequate in vivo validation, and inconsistent methodologies among studies. This review not only consolidates existing knowledge on VP8* biology, structural interactions with receptors, and potential applications, but also critically identifies knowledge gaps, experimental constraints, and emerging controversies such as the uncertain physiological relevance of in vitro glycan binding and the lack of standardized correlates of protection. By integrating recent advances in reverse genetics, nanoparticle platforms, and mRNA vaccines, we offer a forward-looking perspective that goes beyond mere confirmation of published data.We explore advancements in recombinant VP8* technologies, the challenges associated with PoRVA strain diversity, and the potential of molecular biology and vaccinology approaches to enhance intervention strategies.

This publication has 90 references indexed in Scilit: